Case Details
- Citation: [2017] SGHC 322
- Title: NOVARTIS (SINGAPORE) PTE LTD v BRISTOL-MYERS SQUIBB PHARMA COMPANY
- Court: High Court of the Republic of Singapore
- Date of Decision: 20 December 2017
- Originating Process: Originating Summons No 1002 of 2016
- Judge: George Wei J
- Hearing Date: 4 May 2017 (judgment reserved)
- Plaintiff/Applicant: Novartis (Singapore) Pte Ltd (“Novartis”)
- Defendant/Respondent: Bristol-Myers Squibb Pharma Company (“Bristol-Myers”)
- Legal Area: Patents; rectification of the patents register
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed)
- Statutory Framework (as described in judgment): Patents Act; Patents Rules (Cap 221, R 1, 2007 Rev Ed); international instruments including the PCT and EPC (for interpretive guidance)
- Key Procedural Provisions Discussed: Rule 58 and Rule 91 (as framed in the judgment); rectification under s 44 of the Patents Act
- Cases Cited: [2017] SGHC 322 (self-citation as provided in metadata)
- Judgment Length: 70 pages; 20,406 words
Summary
This decision concerns a dispute over the correction of priority-related entries in the Singapore patents register. Novartis, the applicant, sought rectification under s 44 of the Patents Act to reverse corrections made by the Registrar of Patents (“the Registrar”) to Bristol-Myers’s patents. The corrections were made after Bristol-Myers discovered that, during the patent application process, the wrong earlier US patent application number had been entered in the relevant forms supporting the claimed priority date.
The High Court held that the Registrar’s decision to allow the corrections was procedurally irregular in the sense that the Registrar had dispensed with a requirement under r 58 without properly exercising the discretion conferred by that rule. The court also addressed whether Bristol-Myers was entitled to seek correction of the register under r 91, including the principles governing such corrections and the relevance of European Patent Office (EPO) jurisprudence and EPC-based reasoning. Ultimately, the court’s analysis led to the conclusion that the corrections should not stand as made, and the register required rectification.
Although the underlying factual error was essentially clerical (an incorrect US application number entered in the priority documentation), the case is significant because it demonstrates that even seemingly technical corrections can have major substantive consequences for patent validity and infringement risk—particularly where priority determines the relevant state of the art and therefore the scope of enforceable rights.
What Were the Facts of This Case?
Novartis and Bristol-Myers are pharmaceutical companies with competing interests in patent protection for certain inventions. Bristol-Myers was the proprietor of five Singapore patents under the Patents Act. After receiving notice that Novartis was applying for a product licence under the Medicines Act, Bristol-Myers commenced High Court Suit No 1146 of 2015. In that suit, Bristol-Myers sought declarations that Novartis’s intended acts for which the product licence was sought would infringe the Singapore patents, and it sought an injunction to prevent those acts.
A central issue in the infringement proceedings was the priority date claimed by Bristol-Myers for the Singapore patents. Bristol-Myers asserted a priority date of 11 June 1988, which it said derived from an earlier US patent application for the same (or a similar) invention. Novartis’s defence in the infringement suit challenged this priority claim. Novartis argued that the document relied upon by Bristol-Myers in support of the claimed priority date related to a completely different invention and had no connection to the inventions disclosed and claimed in the Singapore patents.
After Novartis filed its defence, Bristol-Myers investigated the prosecution history and discovered that an error had occurred during the application process. Specifically, the wrong earlier US patent application number had been entered in the relevant forms. In other words, the priority claim was supported by an incorrect US application number, even though the intended priority basis was different. This discovery prompted Bristol-Myers to seek administrative correction of the patents register.
Bristol-Myers then filed requests with the Registrar to correct the entries in the Register so that the correct US patent application number would be reflected in support of the claimed priority date. The Registrar granted the requests and made the corrections. Novartis disagreed and took the matter to court by commencing the present originating summons for rectification of the Register under s 44 of the Patents Act. The dispute thus shifted from the substantive question of priority in the infringement suit to the procedural and legal propriety of the Registrar’s correction decisions.
What Were the Key Legal Issues?
The High Court had to decide whether the Registrar’s corrections to the register were lawful and should be reversed. This required the court to examine the statutory and regulatory framework governing corrections to patent documents and register entries, and to determine whether the Registrar had complied with the applicable procedural requirements.
One key issue concerned r 58. The judgment indicates that r 58 involved dispensation by the Registrar in relation to certain procedural steps, including matters connected to priority-related corrections. The court had to consider whether the discretion under r 58 was properly exercised and whether the Registrar was entitled to dispense with the relevant requirement in the circumstances of the case.
A second key issue concerned r 91. The court needed to determine whether Bristol-Myers was entitled to seek correction of the register under r 91, and what principles should be applied when assessing such requests. The judgment also addressed the relationship between Singapore’s correction rules and analogous principles found in the EPC and, by extension, the jurisprudence of the EPO and decisions from the UK patent context. In particular, the court considered whether EPO decisions and EPC-based reasoning were relevant and, if so, how they should be used.
How Did the Court Analyse the Issues?
The court began by setting out the broader patent framework in Singapore, emphasising that Singapore’s Patents Act is based on the UK Patents Act 1977, which in turn is based on the European Patent Convention 1973 (EPC). This background was important because the correction rules and priority concepts in Singapore are closely aligned with those in the UK and EPC systems. The court also explained the role of priority under s 17 of the Patents Act, including that the default priority date is the filing date, but an earlier date may be claimed where there is an earlier application within the preceding 12 months.
In the context of international filings, the court described the Patent Cooperation Treaty (PCT) system and how international applications designating Singapore move into the national phase. The court explained that, where an international application is accorded a filing date under the PCT, that date is treated as the date of filing under the Patents Act, and priority declarations made under the PCT are treated as having been made under s 17(2). This matters because the error in the present case arose during the application process and affected the priority documentation that underpins the substantive patent rights.
Against this framework, the court analysed the procedural irregularity under r 58. The judgment indicates that r 58(1) involved a dispensation by the Registrar, and r 58(2) addressed correction of the priority date. The court’s focus was not merely whether the correction was factually “right” (ie, whether the correct US application number should have been used), but whether the Registrar had followed the rule’s procedural logic and properly exercised the discretion it purported to apply. The court concluded that the application of r 58 was procedurally irregular: the discretion under r 58 was not properly exercised. This conclusion is legally significant because it underscores that correction of priority entries is not an administrative formality; it is a decision that can affect substantive rights and must be made in compliance with the rule’s conditions.
The court then turned to r 91 and the principles applicable to correction of register entries. The judgment references principles under r 88 of the EPC 1973 (and r 139 of the current EPC), and it also discusses corrections and the UK Patents Act. The court considered whether Bristol-Myers could seek correction of the entries under r 91, and it addressed the relevance of EPO decisions. The court’s approach reflects a common method in Singapore patent jurisprudence: where Singapore’s rules are modelled on UK/EPC concepts, the court may look to EPC and EPO jurisprudence for interpretive guidance, while still applying Singapore’s statutory text and procedural structure.
In applying these principles, the court would have been concerned with the nature of the error and the permissible scope of correction. While the error was described as an incorrect US patent application number entered in the relevant forms, the legal question is whether correcting that number amounts to an impermissible alteration of the priority claim, or whether it is a permissible correction of an administrative mistake that reflects the true earlier application intended to support priority. The court’s reasoning indicates that the procedural irregularity under r 58 was enough to undermine the Registrar’s decision-making process, and that the substantive entitlement under r 91 also required careful scrutiny of the applicable correction principles.
Finally, the court addressed other arguments raised by Novartis in favour of refusing correction. Although the extract provided is truncated, the structure of the judgment shows that the court considered multiple grounds. This suggests that the court did not treat the case as a narrow “clerical error” dispute. Instead, it treated the correction request as a matter requiring strict compliance with the correction regime, given the potential effect on priority and, consequently, on the validity and enforceability of the patents.
What Was the Outcome?
The High Court allowed Novartis’s application for rectification of the Register. In practical terms, this meant that the corrections made by the Registrar to reflect the corrected US patent application number in support of the claimed priority date were not upheld. The register therefore required amendment consistent with the court’s determination.
The outcome is particularly consequential because priority dates can determine which prior art is relevant and whether the patents meet novelty and inventive step requirements. By reversing the corrections, the court effectively restored the position that the priority documentation could not be corrected in the manner and on the basis that Bristol-Myers had obtained from the Registrar.
Why Does This Case Matter?
This case matters for patent practitioners in Singapore because it clarifies that correction of register entries—especially those affecting priority—must be carried out within the strict boundaries of the applicable rules. Even where the underlying error appears to be clerical, the Registrar’s discretion and the procedural requirements under the Patents Rules are not merely technicalities. Decisions about priority can have downstream effects on infringement litigation, validity assessments, and the availability of defences grounded in prior art.
From a doctrinal perspective, the judgment is also useful because it engages with the interpretive relationship between Singapore’s correction provisions and analogous provisions in the EPC and UK patent law. The court’s discussion of r 91 and the relevance of EPO decisions provides guidance on how Singapore courts may approach foreign jurisprudence when Singapore rules are modelled on European systems. Practitioners should therefore treat this case as an authority on both (i) the procedural discipline required for corrections and (ii) the method of using EPC/UK principles in interpreting Singapore’s correction regime.
For litigators, the case is a reminder that disputes over priority are often fought on multiple fronts. Here, the infringement suit’s priority challenge was leveraged into a register-rectification proceeding. This illustrates a strategic pathway: where a priority claim is contested, parties may seek to correct or reverse register entries, and the legality of those corrections can become determinative.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including s 17 (priority) and s 44 (rectification of the register)
- Patents Rules (Cap 221, R 1, 2007 Rev Ed), including r 58 and r 91 (as discussed in the judgment)
- Medicines Act (Cap 176, 1985 Rev Ed) (referenced for the context of product licence proceedings)
- Patent Cooperation Treaty (PCT) (discussed for international application and priority mechanics)
- European Patent Convention 1973 (EPC) (discussed for interpretive guidance on correction principles)
- UK Patents Act 1977 (discussed for interpretive guidance on correction principles)
Cases Cited
Source Documents
This article analyses [2017] SGHC 322 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.